{"id":20218168,"updated":"2023-10-19T13:56:33Z","additionalIndexing":"2841","affairType":{"abbreviation":"Fra.","id":14,"name":"Fragestunde. Frage"},"author":{"councillor":{"code":2743,"gender":"f","id":4030,"name":"Birrer-Heimo Prisca","officialDenomination":"Birrer-Heimo"},"faction":{"abbreviation":"Fraktion S","code":"S","id":2,"name":"Sozialdemokratische Fraktion"},"type":"author"},"deposit":{"council":{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N"},"date":"2021-12-08T00:00:00Z","legislativePeriod":51,"session":"5112"},"descriptors":[],"drafts":[{"consultation":{"resolutions":[{"category":{"id":3,"name":"Normal"},"council":{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N"},"date":"2021-12-13T00:00:00Z","text":"Mündliche Beantwortung der Frage","type":82}]},"federalCouncilProposal":{},"index":0,"links":[],"preConsultations":[],"references":[],"relatedDepartments":[{"abbreviation":"EDI","id":4,"name":"Departement des Innern","leading":true}],"states":[{"date":"\/Date(1638918000000+0100)\/","id":24,"name":"Im Rat noch nicht behandelt"},{"date":"\/Date(1639350000000+0100)\/","id":229,"name":"Erledigt"}],"texts":[]}],"language":"de","priorityCouncils":[{"abbreviation":"NR","id":1,"name":"Nationalrat","type":"N","priority":1}],"relatedAffairs":[],"roles":[{"councillor":{"code":2743,"gender":"f","id":4030,"name":"Birrer-Heimo Prisca","officialDenomination":"Birrer-Heimo"},"faction":{"abbreviation":"Fraktion S","code":"S","id":2,"name":"Sozialdemokratische Fraktion"},"type":"author"}],"shortId":"21.8168","state":{"id":229,"name":"Erledigt","doneKey":"0","newKey":0},"texts":[{"type":{"id":5,"name":"Eingereichter Text"},"value":"<p>Am 22. Oktober 2021 hat die EU-Kommission eine Liste der zehn vielversprechendsten Medikamente gegen Covid-19 veröffentlicht: Ronapreve, Xevudy, Evusheld, Molnupiravir, PF-07321332, AT-527, Actemra, Kineret, Olumiant und Lenzilunnab.<\/p><p>- Wie beurteilt der Bundesrat die Entwicklung dieser Medikamente?<\/p><p>- Was unternimmt er, damit diese möglichst bald zugelassen, beschafft und für die Behandlung von Covid-Patienten verwendet werden können?<\/p>"},{"type":{"id":1,"name":"Titel des Geschäftes"},"value":"Zulassung und Beschaffung vielversprechender Covid-19-Medikamente"}],"title":"Zulassung und Beschaffung vielversprechender Covid-19-Medikamente"}